Back to top
more

KALA BIO, Inc. (KALA)

(Delayed Data from NSDQ)

$6.30 USD

6.30
5,711

+0.12 (1.94%)

Updated Apr 26, 2024 03:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Does KALA BIO (KALA) Have the Potential to Rally 152.83% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for KALA BIO (KALA) points to a 152.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

KALA BIO (KALA) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

KALA BIO (KALA) delivered earnings and revenue surprises of -58.60% and 100%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate

by Zacks Equity Research

Dermata (DRMA) gains on positive FDA response for the further development of DMT310 for treating severe to moderate acne.

VYNE Gains on Preclinical Data for IPF Candidate

by Zacks Equity Research

VYNE gains on positive preclinical data evaluating VYN201 for treating idiopathic pulmonary fibrosis.

Madrigal (MDGL) Gains on NASH Treatment's Breakthrough Therapy Tag

by Zacks Equity Research

Madrigal Pharmaceuticals (MDGL) gains on receiving Breakthrough Therapy designation from the FDA for resmetirom.

Gamida Cell (GMDA) Surges on FDA Approval for Omisirge

by Zacks Equity Research

Gamida Cell's (GMDA) shares surge as it receives FDA approval for Omisirge, an allogeneic cell therapy for blood cancer patients.

Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia

by Zacks Equity Research

Humanigen's (HGEN) shares surge after presenting promising early results of its Precision Approach to Chronic Myelomonocytic Leukemia study of lenzilumab in chronic myelomonocytic leukemia.

Alvotech (ALVO) Declines on CRL for Humira's Biosimilar Candidate

by Zacks Equity Research

Alvotech's shares decline as it receives a complete response letter for biosimilar candidate, AVT02, treating autoimmune disorders.

Regulus (RGLS) Surges on Enrollment Completion for RGLS8429

by Zacks Equity Research

Regulus (RGLS) surges as it completes enrollment in the first cohort to evaluate RGLS8429 for kidney disease.

Panbela (PBLA) Enrolls First Patient for Type 1 Diabetes Drug

by Zacks Equity Research

Panbela (PBLA) surges as it enrolls the first patient in the mid-stage clinical study to evaluate CPP-1X-T (Eflornithine tablets) for treating recent-onset type 1 diabetes.

Biotech Stock Roundup: MRNA Provides Update, KALA, IFRX Surge on Regulatory News

by Zacks Equity Research

Regulatory and pipeline updates from Moderna (MRNA) and KALA are the key highlights for the biotech sector.

KALA Up on Fast Track Designation to Lead Ocular Candidate

by Zacks Equity Research

KALA gets Fast Track Designation from the FDA for lead candidate KPI-012 to treat persistent corneal epithelial defects.

Humacyte (HUMA) Completes Enrollment in HAV Technology Study

by Zacks Equity Research

Humacyte (HUMA) surges as it completes patient enrollment in a late-stage clinical study on the human acellular vessel product for vascular access in hemodialysis patients.

Panbela (PBLA) Regains Flynpovi Rights to Treat FAP

by Zacks Equity Research

Panbela (PBLA) shares surge as it regains rights to develop and commercialize Flynpovi for the familial adenomatous polyposis treatment.

Apellis (APLS) Stock Up 50% in Three Months: Here's Why?

by Zacks Equity Research

Apellis (APLS) stock rises 50% in the past three months owing to the approval of Syfovre (pegcetacoplan injection) in February. An encouraging uptake in its first marketed product, Empaveli, also contributed to the surge.

Immunic's (IMUX) Ulcerative Colitis Study Shows Positive Data

by Zacks Equity Research

Immunic (IMUX) reports positive results from the maintenance phase of the phase II study evaluating its lead candidate, vidofludimus calcium, to treat patients with ulcerative colitis.

Palisade (PALI) Enrolls First Patient in LB1148 Study in China

by Zacks Equity Research

Palisade's (PALI) development partner, Newsoara, enrolls first patient in the late-stage clinical study of LB1148 to improve postoperative GI function for patients in China.

Kala Pharmaceuticals (KALA) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Kala Pharmaceuticals (KALA) closed the most recent trading day at $13.71, moving -1.37% from the previous trading session.

InflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment

by Zacks Equity Research

InflaRx (IFRX) shares gain as it receives emergency-use authorization from the FDA for Gohibic (vilobelimab) to treat COVID-19 in terminally-ill patients.

CRISPR (CRSP) & Vertex Complete BLA Submission for Exa-Cel

by Zacks Equity Research

CRISPR (CRSP) and Vertex complete BLA submissions to the FDA for exa-cel for treating sickle cell disease and transfusion-dependent beta-thalassemia.

Kodiak (KOD) Treats First Patient in Diabetic Macular Edema Study

by Zacks Equity Research

Kodiak (KOD) has its first patient in the early-stage study of KSI-501 for treating retinal diseases.

Kala Pharmaceuticals (KALA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Kala Pharmaceuticals (KALA) closed at $14.60, marking a -1.48% move from the previous day.

Emergent's (EBS) Narcan Gets OTC Status for Opioid Overdose

by Zacks Equity Research

Following the FDA approval, Emergent's (EBS) Narcan nasal spray becomes the first OTC product approved for emergency treatment of opioid overdose. This product will be made available by late summer of this year.

Viking (VKTX) Announces Clinical Data for Metabolic Disorders

by Zacks Equity Research

Viking (VKTX) announces positive clinical data, evaluating VK2735 to treat metabolic disorders. It is also initiating an early-stage extension study on the same.

Amicus (FOLD) Gets Pompe Disease Treatment Approval in Europe

by Zacks Equity Research

Amicus (FOLD) receives approval from the European Commission to treat the adult late-onset Pompe disease with Pombiliti (cipaglucosidase alfa).